DATA AVAILABILITY STATEMENT
The data that supports the findings of this study are available in the supplementary material of this article (Tables).
REFERENCES
  1. O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012; 29:437–52.
  2. Fu AZ, Jiang JZ, Reeves JH, et al. Potentially inappropriate medication use and healthcare expenditures in the US community-dwelling elderly. Med Care. 2007;45:472–476.
  3. Atkin PA, Veitch PC, Veitch EM, Ogle SJ. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging. 1999;14:141–52.
  4. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997 Jul;157(14):1531-6.
  5. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003 Dec; 8-22;163(22):2716-24.
  6. Rancourt C, Moisan J, Baillargeon L, et al. Potentially inappropriate prescriptions for older patients in long-term care. BMC Geriatr. 2004; 15; 4: 9
  7. Holt S, Schmeidl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS List. Dtsch Arztebl Int 2010; 107 (31–32): 543–51
  8. Rognstad S, Brekke M, Fetveit A, et al. The Norwegian General Practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients: a modified Delphi study. Scand J Prim Health Care 2009; 27: 153–9
  9. Fick D, Semla T, Beizer J, et al. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. JAGS 2012. doi: 10.1111/j.1532–5415.2012. 03923.x [online].
  10. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. 1991; 151(9):1825-32.
  11. Hamilton H, Gallagher P, Ryan C,et al. Potentially Inappropriate Medications Defined by STOPP Criteria and the Risk of Adverse Drug Events in Older Hospitalized Patients. Arch Intern Med. 2011;171(11):1013-1019.
  12. Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther 2008; 46 (2): 72–83
  13. Delgado Silveira E.  Muñoz García M, Montero Errasquin B, et al. Inappropriate prescription in older patients: the STOPP/START criteria. Rev Esp Geriatr Gerontol. 2009; 44(5):273-9
  14. O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015; 44(2): 213–218.)
  15. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015; 63(11):2227-46.
  16. Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol. 2014;77(1):201-10.
  17. Motl S, Timpe E, Eichner S. Proposal to improve MedWatch: decentralized, regional surveillance of adverse drug reactions. Am J Health Syst Pharm 2004;61:1840–2
  18. Blozik E, Born AM, Stuck AE, et al. Reduction of inappropriate medications among older nursing-home residents: a nurse-led, pre/post-design, intervention study. Drugs Aging. 2010;27:1009–17.
  19. Dunn RL, Harrison D, Ripley TL. The beers criteria as an outpatient screening tool for potentially inappropriate medications. Consult Pharm. 2011;26:754–63.
  20. Thomas RE, Thomas BC. A systematic review of studies of the STOPP/START 2015 and American Geriatric Society Beers 2015 criteria. Curr Aging Sci. 2019; (2):121-154.
  21. Wing E. J. HIV and aging. Int J Infect Dis. 2016; 53, 61-68.
  22. Smi M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet InfecT Dis. 2015; 15, 810-818.
  23. Ware D, Palella FJ Jr, Chew KW, et al. Prevalence and trends of polypharmacy among HIV-positive and negative men in the multicenter AIDS cohort study from 2004 to 2016. PLoS One. 2018; 11;13(9):e0203890
  24. Guaraldi G, Malagoli A, Calcagno A, et al. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years. BMC Geriatr. 2018; 18, 99.
  25. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011; 53, 1130-1139.
  26. Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014; 59, 1787-1797.
  27. Greene M, Steinman MA, McNicholl IR, Valcour VJ. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. Am Geriatr Soc. 2014; 62(3):447-53.
  28. McNicholl IR, Gandhi M, Hare CB, et al. A Pharmacist- Led program  Evaluate and Reduce Polypharmacy and Potentially InappropriatePrescribing in Older HIV-Positive Patients. Pharmacotherapy. 2017; 37(12):1498-1506.
  29. Courlet P, Livio F, Guidi M. Swiss HIVCohort Study. Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. Open Forum Infect Dis. 2019; 21;6(12):ofz531.
  30. Blanco JR, Morillo R, Abril V, et al. Deprescribing of non-antiretroviral therapy in HIV-infected patients. Eur J Clin Pharmacol. 2020; 76(3):305-318. 
  31. Negredo E, Back D, Blanco JR, et al. Aging in HIV-Infected Subjects: A New Scenario and a New View. Biomed Res Int. 2017; 2017:5897298.
  32. Scott LJ. Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection. Drugs. 2020; 80(1):61-72.
  33. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study. Clin Infect Dis. 2020; pii: ciz1243. 
  34. Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. Drugs. 2018; 2;10:215-224. 2018 Nov;78(16):1741-1750.
  35. Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019; 6(9):e576-e587. 
  36. Nozza S, Malagoli A, Maia L, et al. GEPPO Study Group. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. J Antimicrob Chemother. 2017; 72(10):2961.
  37. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019; 67: 674–94.
  38. Livio F, Marzolini C. Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs. 2019; 10: 2042098619880122.